EP0364096B1
(en)
|
1988-09-06 |
2000-03-08 |
Xoma Corporation |
Gene expression elements and the production of chimeric mouse-human antibodies
|
IL89490A0
(en)
*
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Chimeric antibodies directed against metal chelates
|
EP0452508A4
(en)
*
|
1989-11-07 |
1992-11-25 |
The Green Cross Corporation |
Mouse antibody v-region gene fragment and preparation of chimera antibody by using said gene fragment
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
WO1992013077A1
(en)
*
|
1991-01-29 |
1992-08-06 |
Brigham And Women's Hospital |
A cDNA ENCODING THE TYPE I IODOTHYRONINE 5' DEIODINASE
|
US5272078A
(en)
*
|
1991-01-29 |
1993-12-21 |
Brigham And Women's Hospital |
CDNA encoding the type I iodothyronine 5'deiodinase
|
US20050196400A1
(en)
*
|
1991-05-06 |
2005-09-08 |
Xoma Technology Ltd. |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
US5877289A
(en)
*
|
1992-03-05 |
1999-03-02 |
The Scripps Research Institute |
Tissue factor compositions and ligands for the specific coagulation of vasculature
|
US6093399A
(en)
*
|
1992-03-05 |
2000-07-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
US6004555A
(en)
*
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US6036955A
(en)
*
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
FR2724320B1
(fr)
*
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
CA2257357C
(en)
*
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
US6420140B1
(en)
*
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
DK0966533T3
(da)
|
1997-02-07 |
2010-01-04 |
Us Gov Health & Human Serv |
Aktivitetsafhængig neurotrof faktor III (ADNF III).
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
CA2693296C
(en)
*
|
1997-12-08 |
2013-09-10 |
Merck Patent Gmbh |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
WO1999059578A1
(en)
*
|
1998-05-19 |
1999-11-25 |
Research Development Foundation |
Triterpene compositions and methods for use thereof
|
US6350452B1
(en)
|
1998-09-24 |
2002-02-26 |
Promega Corporation |
Apoptosis marker antibodies and methods of use
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US20030143233A1
(en)
*
|
1999-06-07 |
2003-07-31 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
US20030103948A1
(en)
*
|
1999-06-07 |
2003-06-05 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
EP1731531B1
(en)
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Multiple cytokine-antibody complexes
|
WO2001036489A2
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
JP2003535592A
(ja)
*
|
2000-06-06 |
2003-12-02 |
アイデック ファーマスーティカルズ コーポレイション |
ヒトgp39に対する非アゴニスト抗体、含有する組成物、およびその治療的使用
|
EP1294401B1
(en)
|
2000-06-29 |
2007-08-01 |
EMD Lexigen Research Center Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
US20060148732A1
(en)
*
|
2000-11-17 |
2006-07-06 |
Gutterman Jordan U |
Inhibition of NF-kappaB by triterpene compositions
|
AU2002248571B2
(en)
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
JP4309662B2
(ja)
|
2001-05-03 |
2009-08-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍特異的組換え抗体およびその使用
|
AU2002350623A1
(en)
*
|
2001-10-26 |
2003-05-06 |
The Scripps Research Institute |
Targeted thrombosis by tissue factor polypeptides
|
EP2354791A1
(en)
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
DK1537146T3
(da)
|
2002-07-15 |
2011-04-04 |
Univ Texas |
Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
|
EP2436774A3
(en)
|
2002-08-01 |
2012-06-13 |
The Regents of The University of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
WO2004055056A1
(en)
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
EP2397189B1
(en)
|
2003-11-14 |
2015-03-18 |
Brigham and Women's Hospital, Inc. |
Methods of modulating immunity
|
EP1699821B1
(en)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
JP4987484B2
(ja)
|
2004-01-22 |
2012-07-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
補体結合が低下した抗癌抗体
|
JP2008528060A
(ja)
|
2005-01-27 |
2008-07-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ボツリヌス神経毒素を中和する治療的モノクローナル抗体
|
JP4993750B2
(ja)
|
2005-01-27 |
2012-08-08 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン
|
DK1966245T3
(da)
|
2005-12-30 |
2011-07-18 |
Merck Patent Gmbh |
Anti-CD19-Antistoffer med reduceret immunogenicitet
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
JP5866601B2
(ja)
|
2008-06-18 |
2016-02-17 |
ザ テキサス エーアンドエム ユニバーシティ システムThe Texas A&M University System |
医薬組成物の製造方法
|
EP2524233A4
(en)
|
2010-01-15 |
2013-07-31 |
Univ California |
COMPOSITIONS AND METHODS FOR DETECTION OF CANCER
|
EP2525822B1
(en)
|
2010-01-20 |
2017-05-10 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
EP3050901B1
(en)
|
2010-04-09 |
2018-08-29 |
Critical Care Diagnostics, Inc. |
Soluble human st-2 antibodies and assays
|
BR112012027531A2
(pt)
|
2010-04-29 |
2017-08-08 |
Hadasit Medical Res Service And Development Co Ltd |
método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
|
JP5978212B2
(ja)
|
2010-08-24 |
2016-08-24 |
アボット・ラボラトリーズAbbott Laboratories |
Hivコアタンパク質に特異的な抗体及びその使用
|
US20120148559A1
(en)
|
2010-12-01 |
2012-06-14 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
US20150329639A1
(en)
|
2012-12-12 |
2015-11-19 |
University Of Virginia Patent Foundation |
Compositions and methods for regulating erythropoiesis
|
EP2968550B1
(en)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Compositions and methods for treating angiogenesis-related disorders
|
EP3218005B1
(en)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016149368A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
AU2016282986A1
(en)
|
2015-06-26 |
2018-02-01 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
EP3373969A4
(en)
|
2015-11-12 |
2019-08-14 |
Siamab Therapeutics, Inc. |
GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
US12049511B2
(en)
|
2016-11-10 |
2024-07-30 |
Fortis Therapeutics, Inc. |
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
CN108727494A
(zh)
*
|
2017-04-25 |
2018-11-02 |
成都贝爱特生物科技有限公司 |
一种靶向筛选外源基因双整合位点提高人c5单抗表达产量的方法
|
EP3655031A1
(en)
|
2017-07-21 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neisseria meningitidis immunogenic compositions
|
US20200283537A1
(en)
|
2017-11-14 |
2020-09-10 |
University Of Virginia Patent Foundation |
Compositions and methods for making and using bispecific antibodies
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
US20230340086A1
(en)
|
2019-06-19 |
2023-10-26 |
Christopher Roland Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CN115151566A
(zh)
|
2019-11-15 |
2022-10-04 |
普利安特治疗公司 |
用于活化整合素的组合物和方法
|
CN115697403A
(zh)
|
2020-03-10 |
2023-02-03 |
迪赞纳生命科学公开有限公司 |
Il-6/il-6r抗体的组合物及其使用方法
|
AU2021291029A1
(en)
|
2020-06-17 |
2022-11-03 |
Tiziana Life Sciences Plc |
Compositions and methods for augmenting chimeric antigen receptor (CAR) T cell therapies
|
CA3185105A1
(en)
|
2020-07-30 |
2022-02-03 |
Kunwar Shailubhai |
Cd-3 antibodies for the treatment of coronavirus
|
AU2021320333A1
(en)
|
2020-08-07 |
2023-03-30 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting CD46 and methods of use thereof
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
BR112023021297A2
(pt)
|
2021-04-14 |
2023-12-12 |
Villaris Therapeutics Inc |
Anticorpos anti-cd122 e usos dos mesmos
|
EP4323404A1
(en)
|
2021-04-16 |
2024-02-21 |
Tiziana Life Sciences PLC |
Subcutaneous administration of antibodies for the treatment of disease
|
AU2022365121A1
(en)
|
2021-10-14 |
2024-04-18 |
The Brigham And Women's Hospital, Inc. |
Methods of suppressing microglial activation
|
IL312584A
(en)
|
2021-11-09 |
2024-07-01 |
Sensei Biotherapeutics Inc |
ANTI-VISTA antibodies and their uses
|